S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Biocept (BIOC) Stock Forecast, Price & News

-0.05 (-3.36%)
(As of 05/20/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
32,542 shs
Average Volume
87,520 shs
Market Capitalization
$24.34 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive BIOC News and Ratings via Email

Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter.

Biocept logo

About Biocept

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians; clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations; and RT-PCR testing services for COVID-19. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.


StockNews.com Begins Coverage on Biocept (NASDAQ:BIOC)
Biocept (NASDAQ:BIOC) Downgraded by TheStreet
See More Headlines

Industry, Sector and Symbol

Medical laboratories
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$61.25 million
Book Value
$2.23 per share


Net Income
$-2.82 million
Pretax Margin




Free Float
Market Cap
$24.34 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.13 out of 5 stars

Medical Sector

1203rd out of 1,416 stocks

Medical Laboratories Industry

28th out of 32 stocks

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Biocept (NASDAQ:BIOC) Frequently Asked Questions

Is Biocept a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Biocept stock.
View analyst ratings for Biocept
or view top-rated stocks.

When is Biocept's next earnings date?

Biocept is scheduled to release its next quarterly earnings announcement on Wednesday, May 25th 2022.
View our earnings forecast for Biocept

How were Biocept's earnings last quarter?

Biocept, Inc. (NASDAQ:BIOC) posted its quarterly earnings results on Tuesday, April, 5th. The medical research company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.01. Biocept had a negative trailing twelve-month return on equity of 5.35% and a negative net margin of 2.89%. During the same quarter in the previous year, the business posted $0.14 earnings per share.
View Biocept's earnings history

When did Biocept's stock split? How did Biocept's stock split work?

Biocept's stock reverse split on Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 4th 2020. An investor that had 100 shares of Biocept stock prior to the reverse split would have 10 shares after the split.

Who are Biocept's key executives?
Biocept's management team includes the following people:
  • Mr. Samuel D. Riccitelli, Interim Pres, CEO & Chairman (Age 63)
  • Mr. Michael Terry, Sr. VP of Corp. Devel. (Age 67, Pay $306.47k)
  • Dr. Soon Kap Hahn Ph.D., Founder
  • Mr. Antonino Morales, Interim CFO & Director (Age 66)
  • Dr. Philippe J. Marchand Ph.D., Chief Operating Officer (Age 59)
  • Mr. Pavel Tsinberg, Director of Technology Devel.
  • Mr. Darrell Taylor Esq., Sr. VP, Chief Legal Officer & Chief Compliance Officer
  • Mr. David S. Moskowitz R.Ph., MBA, VP of Strategy & Corp. Communications
  • Antonio Paternostro, VP of Sales
  • Dr. Veena M. Singh, Sr. Medical Director (Age 47)
What is Michael Nall's approval rating as Biocept's CEO?

1 employees have rated Biocept CEO Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among Biocept's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Biocept own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

What is Biocept's stock symbol?

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

Who are Biocept's major shareholders?

Biocept's stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.69%), Acadian Asset Management LLC (0.16%), Taylor & Morgan Wealth Management LLC (0.14%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Company insiders that own Biocept stock include David F Hale and David F Hale.
View institutional ownership trends for Biocept

Which institutional investors are selling Biocept stock?

BIOC stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC.
View insider buying and selling activity for Biocept
or view top insider-selling stocks.

Which institutional investors are buying Biocept stock?

BIOC stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Taylor & Morgan Wealth Management LLC, and Group One Trading L.P..
View insider buying and selling activity for Biocept
or or view top insider-buying stocks.

How do I buy shares of Biocept?

Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biocept's stock price today?

One share of BIOC stock can currently be purchased for approximately $1.44.

How much money does Biocept make?

Biocept has a market capitalization of $24.34 million and generates $61.25 million in revenue each year. The medical research company earns $-2.82 million in net income (profit) each year or ($0.100010) on an earnings per share basis.

How many employees does Biocept have?

Biocept employs 104 workers across the globe.

What is Biocept's official website?

The official website for Biocept is www.biocept.com.

How can I contact Biocept?

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at (858) 320-8200, via email at [email protected], or via fax at 858-320-8225.

This page was last updated on 5/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.